179 related articles for article (PubMed ID: 37542062)
21. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.
Iachettini S; Trisciuoglio D; Rotili D; Lucidi A; Salvati E; Zizza P; Di Leo L; Del Bufalo D; Ciriolo MR; Leonetti C; Steegborn C; Mai A; Rizzo A; Biroccio A
Cell Death Dis; 2018 Sep; 9(10):996. PubMed ID: 30250025
[TBL] [Abstract][Full Text] [Related]
22. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
23. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
24. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
27. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects.
Damonte P; Sociali G; Parenti MD; Soncini D; Bauer I; Boero S; Grozio A; Holtey MV; Piacente F; Becherini P; Sanguineti R; Salis A; Damonte G; Cea M; Murone M; Poggi A; Nencioni A; Del Rio A; Bruzzone S
Bioorg Med Chem; 2017 Oct; 25(20):5849-5858. PubMed ID: 28958848
[TBL] [Abstract][Full Text] [Related]
28. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
[TBL] [Abstract][Full Text] [Related]
29. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
30. Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence.
Liu T; Li Z; Tian F
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S96-S107. PubMed ID: 34219513
[TBL] [Abstract][Full Text] [Related]
31. Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells.
Tenhunen J; Kučera T; Huovinen M; Küblbeck J; Bisenieks E; Vigante B; Ogle Z; Duburs G; Doležal M; Moaddel R; Lahtela-Kakkonen M; Rahnasto-Rilla M
Biomed Pharmacother; 2021 Jun; 138():111452. PubMed ID: 33684691
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
33. SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Ioris RM; Galié M; Ramadori G; Anderson JG; Charollais A; Konstantinidou G; Brenachot X; Aras E; Goga A; Ceglia N; Sebastián C; Martinvalet D; Mostoslavsky R; Baldi P; Coppari R
Cell Rep; 2017 Feb; 18(8):1858-1868. PubMed ID: 28228253
[TBL] [Abstract][Full Text] [Related]
34. Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer.
Bao GQ; Shen BY; Pan CP; Zhang YJ; Shi MM; Peng CH
Toxicol Lett; 2013 Sep; 222(1):23-35. PubMed ID: 23845849
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
Yau CY; Wheeler JJ; Sutton KL; Hedley DW
Cancer Res; 2005 Feb; 65(4):1497-504. PubMed ID: 15735038
[TBL] [Abstract][Full Text] [Related]
36. Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling.
Tian J; Yuan L
Biomed Pharmacother; 2018 Oct; 106():109-116. PubMed ID: 29957460
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
Tian X; Hao K; Qin C; Xie K; Xie X; Yang Y
Dig Dis Sci; 2013 Sep; 58(9):2705-12. PubMed ID: 23589145
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
Sun W; Chen X; Huang S; Li W; Tian C; Yang S; Li L
Bioorg Med Chem Lett; 2020 Aug; 30(16):127215. PubMed ID: 32631504
[TBL] [Abstract][Full Text] [Related]
40. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Lee HS; Park SB; Kim SA; Kwon SK; Cha H; Lee DY; Ro S; Cho JM; Song SY
Sci Rep; 2017 Jan; 7():41615. PubMed ID: 28134290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
